General
Preferred name
CVN424
Synonyms
1-{2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-{[(3R)-oxolan-3-yl]amino}-5H,6H,7H,8H-pyrido[3,4-b]pyrazin-6-yl}ethan-1-one ()
P&D ID
PD154884
CAS
2254706-21-1
Tags
available
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
CVN424 is a first-in-class, clinical stage, nondopaminergic inverse agonist of GPR6. It is orally bioavailable, and can penetrate the CNS . In in vivo Parkinson's disease models, inhibiting GPR6 activity with CVN424 normalises both activity in basal ganglia circuitry and motor behaviour.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
3
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
8
Molecular Weight
473.22
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
2
cLogP
2.91
TPSA
79.82
Fraction CSP3
0.54
Chiral centers
1.0
Largest ring
6.0
QED
0.72
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
GPR6
Source data
